Ne­glect­ed on Wall Street, lit­tle Stealth Bio finds an af­flu­ent chum with $30M in cash and high hopes for their PhI­II drug

Stealth Bio­Ther­a­peu­tics nev­er had much luck at gain­ing the at­ten­tion of Wall Street $MI­TO while strug­gling to ad­vance its late-stage drug for mi­to­chon­dr­i­al dis­ease. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER